EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Randomized Controlled Trial of Remimazolam Compared with Placebo in Japanese Patients Undergoing Colonoscopy: A Phase III, Investigator-Initiated Trial

Ryoji Ichijima, Hisatomo Ikehara, Hiroyuki Ono, Kinichi Hotta, Daisuke Yamaguchi, Mitsuru Esaki, Yosuke Minoda, Yasuhiko Nagata, Kanako Ogura, Shinsuke Kiriyama, Tetsuya Sumiyoshi, Yuichi Kanmura

Digestion · 2024

DOI: 10.1159/000540527 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Digestion, 2024. Verfasst von Ryoji Ichijima und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Medicine Nihon University School of Medicine, Tokyo, Japan, ryoji0331@yahoo.co.jp. Hauptthemen laut MEDLINE: Colonoscopy, Hypnotics and Sedatives, Benzodiazepines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

We conducted an investigator-initiated clinical trial in which remimazolam was used to achieve sedation in patients undergoing colonoscopies.

Methods

This multicenter, double-blind, placebo-controlled, phase III investigator-initiated trial included patients who underwent colonoscopy under sedation with remimazolam (initial dose: 3 mg; additional dose: 1 mg) or normal saline (placebo). The primary endpoint of the study was the successful sedation rate during colonoscopy, defined as achieving a Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) score of ≤4 before the procedure, maintaining this score throughout colonoscopy, and requiring no more than five additional drug doses per 15 min.

Results

The sedation success rate was 95.0% (38/40 patients) in the remimazolam group and 0.0% (0/11 patients) in the placebo group (p < 0.01). The time from the end of procedure to regaining consciousness was 0.0 (interquartile range: 0.0–0.0) min in both groups. The time from the end of the procedure to ambulation was 5.0 (interquartile range: 0.0–10.0) min in the remimazolam group and 0.0 (interquartile range: 0.0–0.0) min in the placebo group (p = 0.02). Serious adverse events were not observed.

Conclusion

The use of remimazolam to achieve sedation in Japanese patients undergoing colonoscopy was more effective than placebo.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ColonoscopyHypnotics and SedativesBenzodiazepinesHumansDouble-Blind MethodFemaleMaleMiddle AgedAgedJapanProcedural SedationAdultTreatment OutcomeEast Asian People

Stichwörter der Autor:innen

ColonoscopyPlaceboRandomized control trialRemimazolamSedation

Substanzen

remimazolamHypnotics and SedativesBenzodiazepines

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Medicine Nihon University School of Medicine, Tokyo, Japan, ryoji0331@yahoo.co.jp.
  • Department of Gastroenterology, Kiriyama Clinic, Takasaki, Japan, ryoji0331@yahoo.co.jp.
  • Division of Gastroenterology and Hepatology, Department of Medicine Nihon University School of Medicine, Tokyo, Japan.
  • Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
  • Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
  • Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan.

Zitieren

APA

Ichijima, R., Ikehara, H., Ono, H., Hotta, K., Yamaguchi, D., Esaki, M., Minoda, Y., Nagata, Y., Ogura, K., Kiriyama, S., Sumiyoshi, T., & Kanmura, Y. (2024). Randomized Controlled Trial of Remimazolam Compared with Placebo in Japanese Patients Undergoing Colonoscopy: A Phase III, Investigator-Initiated Trial. Digestion. https://doi.org/10.1159/000540527

Vancouver

Ichijima R, Ikehara H, Ono H, Hotta K, Yamaguchi D, Esaki M, et al. Randomized Controlled Trial of Remimazolam Compared with Placebo in Japanese Patients Undergoing Colonoscopy: A Phase III, Investigator-Initiated Trial. Digestion. 2024. doi:10.1159/000540527

BibTeX
@article{Ichijima2024,
  author = {Ichijima, Ryoji and Ikehara, Hisatomo and Ono, Hiroyuki and Hotta, Kinichi and Yamaguchi, Daisuke and Esaki, Mitsuru and Minoda, Yosuke and Nagata, Yasuhiko and Ogura, Kanako and Kiriyama, Shinsuke and Sumiyoshi, Tetsuya and Kanmura, Yuichi},
  title = {Randomized Controlled Trial of Remimazolam Compared with Placebo in Japanese Patients Undergoing Colonoscopy: A Phase III, Investigator-Initiated Trial},
  journal = {Digestion},
  year = {2024},
  doi = {10.1159/000540527}
}
Kostenlos starten →